Poles MA, Dieterich DT
University of California, Los Angeles, Division of Digestive Diseases, Center for the Health Sciences 44-138, 10833 Le Conte Avenue, Los Angeles, CA 90095-1684, USA.
Curr Infect Dis Rep. 2000 Apr;2(2):177-184. doi: 10.1007/s11908-000-0031-y.
As the life expectancy of patients with HIV infection increases, greater attention will need to be focused on concurrent illnesses, such as viral hepatitis, that may increase mid- to long-range morbidity and mortality. The incidence of viral hepatitis is increased in patients with HIV disease, reflecting the epidemiologic risks that these two conditions share. Coinfection with HIV seems to adversely affect the natural history of hepatitis C but may actually reduce the hepatic damage associated with hepatitis B. Immunosuppression due to HIV does not seem to significantly affect hepatitis A, E, or G. Clinicians have been reluctant to treat viral hepatitis in the HIV-infected population, but this therapeutic nihilism is unwarranted. Most studies have concluded that the treatment of hepatitis C in HIV-infected patients results in an initial efficacy and a long-term response similar to those seen in the HIV-seronegative population. Although the efficacy of interferon is reduced against hepatitis B, some nucleoside analogues are effective.
随着HIV感染患者预期寿命的延长,需要更加关注诸如病毒性肝炎等并存疾病,这些疾病可能会增加中长期发病率和死亡率。HIV疾病患者中病毒性肝炎的发病率有所上升,这反映了这两种疾病共有的流行病学风险。HIV合并感染似乎会对丙型肝炎的自然病程产生不利影响,但实际上可能会减轻与乙型肝炎相关的肝损伤。HIV导致的免疫抑制似乎不会显著影响甲型、戊型或庚型肝炎。临床医生一直不愿对HIV感染人群的病毒性肝炎进行治疗,但这种治疗虚无主义是没有根据的。大多数研究得出结论,HIV感染患者丙型肝炎的治疗效果与HIV血清阴性人群相似,有初步疗效和长期反应。虽然干扰素对乙型肝炎的疗效有所降低,但一些核苷类似物是有效的。